紫杉醇的化疗方案治疗晚期肿瘤临床疗效观察  

The clinical observation and adverse reactions analysis on paclitaxel in the treatment of advanced cancer

作　　者：张丽莹[1] 郭仁宏[1] 孙志华[1] 吴楠[1] 

机构地区：[1]江苏省肿瘤医院,江苏南京210009

出　　处：《实用临床医药杂志》2011年第9期67-68,80,共3页Journal of Clinical Medicine in Practice

摘　　要：目的观察紫杉醇治疗晚期肿瘤的临床疗效及不良反应。方法对2009年1月～2010年7月门诊化疗中心收治的198例接受紫杉醇治疗的晚期肿瘤患者临床资料进行回顾性分析,统计临床治疗效果及不良反应。结果 198例患者中,完全缓解(CR)29例,部分缓解(PR)90例,稳定(SD)52例,进展(PD)27例,临床治疗有效率60.1%。198例患者均出现骨髓抑制、不同程度的脱发;160例出现消化道反应;133例出现肌肉关节疼痛;124例患者发生周围神经毒性;15例患者发生轻度肾功能损害;3例出现过敏反应。结论含紫杉醇的化疗方案是治疗晚期肿瘤的有效方法。Objective To observe the clinical efficacy and adverse reactions on paclitaxel in the treatment of advanced cancer.Methods 198 patients who received paclitaxel in the treatment of advanced cancer from January 2009 to July 2010 in our hospital were retrospectively analyzed in terms of clinical data,statistics,clinical efficacy and adverse reactions.Results Among 198 cases,there were 29 CR,90 PR,52 SD,and 27 PD.The total clinical effective rate was 60.1%.198 cases of bone marrow suppression occurred in patients with 100%（198/198）;gastrointestinal symptoms 80.8%（160/198）;muscle and joint pain 67.17%（133/198）;100%（198/198） patients with varying degrees of hair loss;62.9%（124/198） patients with peripheral nerve toxicity;7.8%（15/198） patients had mild renal impairment;allergic reaction was 1.51%（3/198）.Conclusion The paclitaxel-based chemotherapy is an effective method for the treatment of advanced cancer.

关 键 词：肿瘤 晚期 紫杉醇 临床观察 不良反应 

分 类 号：R730.53[医药卫生—肿瘤]